Pfizer/Lilly Discontinue Tanezumab, The Likely End For A Class Dogged By Safety
Executive Summary
The nerve growth factor inhibitor for osteoarthritis pain is one of the last still in development after safety largely sidetracked the class of drugs.
You may also be interested in...
Do Patients Understand The Term ‘Median’ In Advertising? US FDA Aims To Find Out
In first Rx advertising research project of 2023, FDA will survey consumers on how they interpret quantitative claims in DTC ads. Lilly questions design of another study examining relative importance of product information, citing FDA comments at tanezumab advisory committee.
Vertex Is The First To Get NaV1.8 To Proof Of Concept For Pain
Chief scientific officer David Altshuler talked to Scrip about the late-stage development plan for a drug that could represent a blockbuster-sized commercial opportunity, after two Phase II studies testing VX-548 met their primary endpoints.
Pfizer’s Tanezumab REMS Cannot Make Benefit-Risk Positive, US FDA Panel Says
Panelists say REMS would need data on long-term safety and progression of joint damage after discontinuation. In 19-1 vote, advisory committee concludes proposed Risk Evaluation and Mitigation Strategy will not ensure the anti-nerve growth factor’s modest benefits outweigh risks of joint destruction in osteoarthritis patients.